Tesamorelin 20mg

Description

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release endogenous growth hormone in a physiologically normal pulsatile pattern. Unlike direct GH administration, Tesamorelin preserves the natural feedback mechanisms of the hypothalamic-pituitary axis.

Mechanism of Action:

• Binds GHRH receptors on pituitary somatotrophs to stimulate endogenous GH secretion.
• Elevates IGF-1 levels downstream, supporting anabolic, lipolytic, and cellular-repair processes.
• Preferentially reduces visceral adipose tissue without the supraphysiologic side-effect profile associated with exogenous GH administration.

Research Highlights:

FDA-approved for HIV-associated lipodystrophy, Tesamorelin has demonstrated consistent visceral fat reduction of 15–20% in clinical trials. Research models also demonstrate improvements in cognitive function, lipid profiles, and lean mass preservation.

References: PMID 20956625 | J Clin Endocrinol Metab 2010 | Lancet HIV 2019

Potential Applications (for research use):

• Visceral adiposity and body-composition models
• GH/IGF-1 axis and pituitary regulation research
• Metabolic function and lipid-profile studies

Stacking Callouts:

Frequently paired with Ipamorelin or CJC-1295 (No DAC) for enhanced GH-pulse amplitude and IGF-1 optimization.

For laboratory and research use only. Not for human consumption.